// App-Quantinova.ai

580 : Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE

Researchers

Presenter

  • Saroj Vadhan-Raj

Principal Investigators

  • Xiao Zhou

  • Gauri R. Varadhachary

  • Michael J. Overman

  • Javle Milind

  • David Fogelman

  • Rachna Shroff

  • Carlos E. Bueso-Ramos

  • Martin Nguyen

  • Xuemei Wang

  • Robert A. Wolff

  • James L. Abbruzzese

Medical Centers

  • Quantitative Research, Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Sarcoma Medical Oncology/Section of Cytokines & Supportive Oncology, UT MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Venous thrombosis

  • Deep vein thrombosis

  • Pancreatic cancer

  • Solid malignancies

Biomarkers

  • Adenomatous Polyposis Coli

  • Alpha-tubulin N-acetyltransferase 1

  • D-dimer

Drug/Treatment

  • dalteparin Subcutaneous

  • Evithrom

  • Tedelparin

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved